Perampanel
Back to searchMolecule Structure
Scientific Name
Perampanel
Description of the Drug
Perampanel is a non-competitive AMPA glutamate receptor antagonist used to treat partial-onset seizures with or without secondarily generalized seizures, and as adjunctive treatment of primary generalized tonic-clonic seizures in patients with epilepsy.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB08883
http://www.drugbank.ca/drugs/DB08883
Brand Name(s)
Fycompa
Company Owner(s)
Accord Healthcare Inc, Eisai Inc, Teva Pharmaceuticals Usa Inc
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
Glutamate receptor ionotropic AMPA | PROTEIN COMPLEX GROUP | ANTAGONIST | CHEMBL2096670 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL194370 | |
Human Metabolome Database | HMDB0256305 | |
DrugBank | DB08883 | |
PubChem: Thomson Pharma | 14896254 | |
PubChem | 9924495 | |
LINCS | LSM-45792 | |
Nikkaji | J2.400.987D | |
PDBe | 6ZP | |
BindingDB | 50184410 | |
EPA CompTox Dashboard | DTXSID80191501 | |
DrugCentral | 4684 | |
ChemicalBook | CB12598797 | |
Guide to Pharmacology | 7050 | |
rxnorm | PERAMPANEL | FYCOMPA |
PubChem: Drugs of the Future | 136349971 | |
ChEBI | 71013 | |
ZINC | ZINC000030691797 |